טוען...
Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years
The mechanistic target of rapamycin (mTOR) is a central regulator in cell growth, activation, proliferation, and survival. Activation of the mTOR pathway underlies the pathogenesis of systemic lupus erythematosus (SLE). While mTOR activation and its therapeutic reversal were originally discovered in...
שמור ב:
| הוצא לאור ב: | Curr Rheumatol Rep |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5314949/ https://ncbi.nlm.nih.gov/pubmed/27812954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11926-016-0622-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|